Healthcare

Pain Management Therapeutics Market 2021| Trends, Demand, Scope & forecast to 2030 focusing key players: Teva Pharmaceutical, Pfizer, Abbott, Mallinckrodt Pharmaceuticals, Endo International

Share This Article

Pain Management Therapeutics Market size was accounted  at USD 69.54 billion in 2020 and is projected to reach USD 107.3 billion by 2030, growing at compound annual growth rate (CAGR) of 4.3% during the forecast period 2021 to 2030.

Get the sample copy of this report@ https://www.precedenceresearch.com/sample/1224

Growth Factors:

Factors such as increasing geriatric population, rising number of accidents worldwide, growing prevalence of chronic disorders, rise in per-capita healthcare expenditure, increasing number of surgeries, constant approvals for new easy-to-use and effective medications, increasing cases of cancer in developing regions, and growing research and development expenditure are propelling the pain management therapeutics market expansion across the globe. Additional aspects that are estimated to fuel this industry are strong product pipeline of major manufacturers and technological innovations. A constant rise in the cases of chronic disorders throughout the world is pushing the business to grow at a rapid pace. Early detection of ailment raises the chances for a decreased mortality rate. According to the American Cancer Society, around 1.76 million new cancer cases were diagnosed in 2019 and more than 606,000 cancer deaths reported in the United States alone. The number of elderly persons is also on the rise globally. According to the World Health Organization, the geriatric population is projected to hit 1.5 billion by the year 2040, which will represent around 16% of the entire world population.

Growing investment in the research and development activities aimed at improving the efficiency of existing therapy options along with developing new treatments is driving the market globally. The short-term as well as long-term strategies of leading biotech and pharma companies play a vital role in determining market trends. Short term policies aim at tackling patenting concerns and display an immediate effect on the market. Whereas, long term policies focus on upgrading R&D, focused treatment approaches, and unified network representations.

Report Highlights Details
Market Size USD 107.3 Billion by 2030
Growth Rate CAGR of 4.3% from 2021 to 2030
Base Year 2020
Historic Data 2017 to 2020
Forecast Period 2021 to 2030
Segments Covered Drug Class, Indication, Distribution Channel
Regional Scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA)
Companies Mentioned Teva Pharmaceutical, Pfizer, Abbott, Mallinckrodt Pharmaceuticals, Endo International, GlaxoSmithKline, AstraZeneca, Depomed, Merck, Novartis

 Ask here for customization study@ https://www.precedenceresearch.com/customization/1224

Key Players

Teva Pharmaceutical

Pfizer

Abbott

Mallinckrodt Pharmaceuticals

Endo International

GlaxoSmithKline

AstraZeneca

Depomed

Merck

Novartis

Overview of the Study

This market report studies market dynamics, status and outlook especially in North America, Europe and Asia-Pacific, Latin America, Middle East and Africa. This research report offers scenario and forecast (revenue/volume). This report also studies global market prominence, competitive landscape, market share, growth rate, market dynamics such as drivers, restraints and opportunities, and distributors and sales channel.

This research study also integrates Industry Chain analysis and Porter’s Five Forces Analysis. Further, this report offers competitive scenario which comprises collaborations, market concentration rate and expansions, mergers & acquisitions undertaken by companies.

Buy this Research Report study@ https://www.precedenceresearch.com/checkout/1224

Research Methodology

Secondary Research

It involves company databases such as Hoover’s: This assists us recognize financial information, structure of the market participants and industry competitive landscape.

The secondary research sources referred in the process are as follows:

  • Governmental bodies, and organizations creating economic policies
  • National and international social welfare institutions
  • Company websites, financial reports and SEC filings, broker and investor reports
  • Related patent and regulatory databases
  • Statistical databases and market reports
  • Corporate Presentations, news, press release, and specification sheet of Manufacturers

Primary Research

Primary research includes face-to face interviews, online surveys, and telephonic interviews.

  • Means of primary research: Email interactions, telephonic discussions and

Questionnaire based research etc.

  • In order to validate our research findings and analysis we conduct primary interviews

of key industry participants. Insights from primary respondents help in validating the

secondary research findings. It also develops Research Team’s expertise and market

understanding.

Market Segmentation

By Drug Class

  • NSAIDs
  • Opioids
  • Anesthetics
  • Antidepressants
  • Anticonvulsants
  • Others

By Indication

  • Arthritic Pain
  • Neuropathic Pain
  • Chronic Back Pain
  • Post-Operative Pain
  • Cancer Pain
  • Others

By Distribution Channel

  • Online Pharmacy
  • Retail Pharmacy
  • Hospital Pharmacy

Why should you invest in this report?

If you are aiming to enter the global Pain Management Therapeutics market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for Pain Management Therapeutics are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2021-2030 so that you can plan your strategies to enter this market accordingly.

Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions& Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Pain Management Therapeutics Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope

Chapter 5. COVID 19 Impact on Pain Management Therapeutics Market

5.1. Covid-19: Pain Management Therapeutics Industry Impact
5.2. Pain Management Therapeutics Business Impact Assessment: Covid-19
5.2.1. Services Challenges/Disruption
5.2.2. Market Trends and Pain Management Therapeutics Opportunities in the COVID-19 Landscape for Major Markets
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for Pain Management Therapeutics Market Players to deal with Covid-19 Pandemic Scenario

Chapter 6. Pain Management Therapeutics Market Dynamics Analysis and Trends

6.1. Market Dynamics
6.1.1. Market Drivers
6.1.1.1. Growing prevalence of chronic disorders
6.1.1.2. Increasing geriatric population
6.1.2. Market Restraints
6.1.2.1. Side-effects associated with some pain management medications
6.1.3. Market Opportunities
6.1.3.1. Growing research and development expenditure
6.1.3.2. Technological advancements

Chapter 7. Global Pain Management Therapeutics Market: Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. Pain Management Therapeutics Market Revenue by Market Players (2016 -2019)
7.1.1.2. Pain Management Therapeutics Market Revenue Market Share by Market Players (2016 -2019)
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Product Portfolio Expansion, Geographic Expansion, Drug Class Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Market Players Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of End-users

Chapter 8. Global Pain Management Therapeutics Market, By Drug Class

8.1. Pain Management Therapeutics Market, by Drug Class, 2017 – 2030
8.1.1. NSAIDs
8.1.1.1. Market Revenue and Forecast (2017 – 2030)
8.1.2. Opioids
8.1.2.1. Market Revenue and Forecast (2017 – 2030)
8.1.3. Anesthetics
8.1.3.1. Market Revenue and Forecast (2017 – 2030)
8.1.4. Antidepressants
8.1.4.1. Market Revenue and Forecast (2017 – 2030)
8.1.5. Anticonvulsants
8.1.5.1. Market Revenue and Forecast (2017 – 2030)
8.1.6. Others
8.1.6.1. Market Revenue and Forecast (2017 – 2030)

Chapter 9. Global Pain Management Therapeutics Market, By Indication

9.1. Pain Management Therapeutics Market, by Indication, 2017 – 2030
9.1.1. Arthritic Pain
9.1.1.1. Market Revenue and Forecast (2017 – 2030)
9.1.2. Neuropathic Pain
9.1.2.1. Market Revenue and Forecast (2017 – 2030)
9.1.3. Chronic Back Pain
9.1.3.1. Market Revenue and Forecast (2017 – 2030)
9.1.4. Post-Operative Pain
9.1.4.1. Market Revenue and Forecast (2017 – 2030)
9.1.5. Cancer Pain
9.1.5.1. Market Revenue and Forecast (2017 – 2030)
9.1.6. Others
9.1.6.1. Market Revenue and Forecast (2017 – 2030)

Chapter 10. Global Pain Management Therapeutics Market, By Distribution Channel

10.1. Pain Management Therapeutics Market, by Distribution Channel, 2017 – 2030
10.1.1. Online Pharmacy
10.1.1.1. Market Revenue and Forecast (2017 – 2030)
10.1.2. Retail Pharmacy
10.1.2.1. Market Revenue and Forecast (2017 – 2030)
10.1.3. Hospital Pharmacy
10.1.3.1. Market Revenue and Forecast (2017 – 2030)

Chapter 11. Global Pain Management Therapeutics Market, Regional Estimates and Trend Forecast

11.1. North America
11.1.1. Market Revenue Forecast by Drug Class(2017 – 2030)
11.1.2. Market Revenue Forecast by Indication(2017 – 2030)
11.1.3. Market Revenue Forecast by Distribution Channel (2017 – 2030)
11.1.4. U.S
11.1.4.1. Market Revenue Forecast (2017 – 2030)
11.1.5. Canada
11.1.5.1. Market Revenue Forecast (2017 – 2030)
11.2. Europe
11.2.1. Market Revenue Forecast by Drug Class (2017 – 2030)
11.2.2. Market Revenue Forecast by Indication (2017 – 2030)
11.2.3. Market Revenue Forecast by Distribution Channel (2017 – 2030)
11.2.4. UK
11.2.4.1. Market Revenue Forecast (2017 – 2030)
11.2.5. Germany
11.2.5.1. Market Revenue Forecast (2017 – 2030)
11.2.6. France
11.2.6.1. Market Revenue Forecast (2017 – 2030)
11.2.7. Rest of EU
11.2.7.1. Market Revenue Forecast (2017 – 2030)
11.3. Asia Pacific (APAC)
11.3.1. Market Revenue Forecast by Drug Class (2017 – 2030)
11.3.2. Market Revenue Forecast by Indication (2017 – 2030)
11.3.3. Market Revenue Forecast by Distribution Channel (2017 – 2030)
11.3.4. China
11.3.4.1. Market Revenue Forecast (2017 – 2030)
11.3.5. India
11.3.5.1. Market Revenue Forecast (2017 – 2030)
11.3.6. Japan
11.3.6.1. Market Revenue Forecast (2017 – 2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue Forecast (2017 – 2030)
11.4. LATAM
11.4.1. Market Revenue Forecast by Drug Class (2017 – 2030)
11.4.2. Market Revenue Forecast by Indication (2017 – 2030)
11.4.3. Market Revenue Forecast by Distribution Channel (2017 – 2030)
11.4.4. Brazil
11.4.4.1. Market Revenue Forecast (2017 – 2030)
11.4.5. Rest of LATAM
11.4.5.1. Market Revenue Forecast (2017 – 2030)
11.5. Middle East and Africa (MEA)
11.5.1. Market Revenue Forecast by Drug Class (2017 – 2030)
11.5.2. Market Revenue Forecast by Indication (2017 – 2030)
11.5.3. Market Revenue Forecast by Distribution Channel (2017 – 2030)
11.5.4. GCC
11.5.4.1. Market Revenue Forecast (2017 – 2030)
11.5.5. North Africa
11.5.5.1. Market Revenue Forecast (2017 – 2030)
11.5.6. South Africa
11.5.6.1. Market Revenue Forecast (2017 – 2030)
11.5.7. Rest of MEA
11.5.7.1. Market Revenue Forecast (2017 – 2030)

Chapter 12. Company Profiles

12.1. Teva Pharmaceutical
12.1.1. Company Overview, Business Information, Regional Presence
12.1.2. Product Portfolio Analysis
12.1.2.1. Product Details, Specification, Distribution Channel
12.1.3. Revenue, Price, and Gross Margin (2017 – 2020)
12.1.4. Recent Developments and Strategies
12.2. Pfizer
12.2.1. Company Overview, Business Information, Regional Presence
12.2.2. Product Portfolio Analysis
12.2.2.1. Product Details, Specification, Distribution Channel
12.2.3. Revenue, Price, and Gross Margin (2017 – 2020)
12.2.4. Recent Developments and Strategies
12.3. Abbott
12.3.1. Company Overview, Business Information, Regional Presence
12.3.2. Product Portfolio Analysis
12.3.2.1. Product Details, Specification, Distribution Channel
12.3.3. Revenue, Price, and Gross Margin (2017 – 2020)
12.3.4. Recent Developments and Strategies
12.4. Mallinckrodt Pharmaceuticals
12.4.1. Company Overview, Business Information, Regional Presence
12.4.2. Product Portfolio Analysis
12.4.2.1. Product Details, Specification, Distribution Channel
12.4.3. Revenue, Price, and Gross Margin (2017 – 2020)
12.4.4. Recent Developments and Strategies
12.5. Endo International
12.5.1. Company Overview, Business Information, Regional Presence
12.5.2. Product Portfolio Analysis
12.5.2.1. Product Details, Specification, Distribution Channel
12.5.3. Revenue, Price, and Gross Margin (2017 – 2020)
12.5.4. Recent Developments and Strategies
12.6. GlaxoSmithKline
12.6.1. Company Overview, Business Information, Regional Presence
12.6.2. Product Portfolio Analysis
12.6.2.1. Product Details, Specification, Distribution Channel
12.6.3. Revenue, Price, and Gross Margin (2017 – 2020)
12.6.4. Recent Developments and Strategies
12.7. AstraZeneca
12.7.1. Company Overview, Business Information, Regional Presence
12.7.2. Product Portfolio Analysis
12.7.2.1. Product Details, Specification, Distribution Channel
12.7.3. Revenue, Price, and Gross Margin (2017 – 2020)
12.7.4. Recent Developments and Strategies
12.8. Depomed
12.8.1. Company Overview, Business Information, Regional Presence
12.8.2. Product Portfolio Analysis
12.8.2.1. Product Details, Specification, Distribution Channel
12.8.3. Revenue, Price, and Gross Margin (2017 – 2020)
12.8.4. Recent Developments and Strategies
12.9. Merck
12.9.1. Company Overview, Business Information, Regional Presence
12.9.2. Product Portfolio Analysis
12.9.2.1. Product Details, Specification, Distribution Channel
12.9.3. Revenue, Price, and Gross Margin (2017 – 2020)
12.9.4. Recent Developments and Strategies
12.10. Novartis
12.10.1. Company Overview, Business Information, Regional Presence
12.10.2. Product Portfolio Analysis
12.10.2.1. Product Details, Specification, Distribution Channel
12.10.3. Revenue, Price, and Gross Margin (2017 – 2020)
12.10.4. Recent Developments and Strategies

Chapter 13. Appendix

13.1. About Us
13.2. Glossary of Terms

Buy this Research Report study@ https://www.precedenceresearch.com/checkout/1224

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 9197 992 333

About Us

Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.

For Latest Update Follow Us:

https://www.linkedin.com/company/precedence-research/

https://www.facebook.com/precedenceresearch/

https://twitter.com/Precedence_R

Show More

Related Articles

Back to top button